VY TAU01
Alternative Names: VY-TAU01Latest Information Update: 23 May 2024
At a glance
- Originator Voyager Therapeutics
- Class Antidementias; Gene therapies; Monoclonal antibodies
- Mechanism of Action Gene transference; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease